argenx vs UnitedHealth stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
argenx is more profitable, grows faster and has less debt. UnitedHealth is cheaper for its profits.
Side by side
| argenx | UnitedHealth | |
|---|---|---|
| $60.4 billion | $365 billion | |
| 31.1% | 2.7% | |
| +116.2% | +11.7% | |
| 46.7× | 30.3× | |
| Net cash | 2.3 years | |
| 11.7% | 8.8% | |
| – | 2.3% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: argenx vs AbbVie · argenx vs Johnson & Johnson · argenx vs Eli Lilly · argenx vs Merck & · UnitedHealth vs AstraZeneca · UnitedHealth vs Bristol-Myers Squibb · UnitedHealth vs Boston Scientific · UnitedHealth vs The Cigna Group

